Nelson Comments on Decline in Accounting Enforcement Cases by SEC
November 4, 2018
Gulf Times
Of Counsel Margaret G. Nelson was quoted in a Gulf Times article, “Accounting enforcement cases at SEC drop in 2018,” about a significant decline in the overall number of financial reporting related cases brought by the SEC this year compared to 2017.
Nelson said accounting fraud cases are very complex. “The SEC is investigating not only the issuer itself, but the auditor. That can take a long time,” she said.
Auditor-focused cases have also dropped, even though SEC officials say that gatekeepers, including auditors, remain a focus, Nelson added. “We saw plenty of fraud cases or material misstatement cases brought against the issuer. But you didn’t see a companion case brought against the auditor,” she said.
Nelson said accounting fraud cases are very complex. “The SEC is investigating not only the issuer itself, but the auditor. That can take a long time,” she said.
Auditor-focused cases have also dropped, even though SEC officials say that gatekeepers, including auditors, remain a focus, Nelson added. “We saw plenty of fraud cases or material misstatement cases brought against the issuer. But you didn’t see a companion case brought against the auditor,” she said.
People
Related News
July 21, 2025
In the News
Nicholas O'Keefe Assesses 'Golden Share' in US Steel Deal
Foley & Lardner LLP partner Nicholas O'Keefe commented on the 'golden share' arrangement included as part of the approval of Nippon Steel's acquisition of U.S. Steel in Agenda, a Financial Times publication.
July 18, 2025
In the News
Matt Caplan Featured for Arrival to Foley – 'It's an exciting time'
Foley & Lardner LLP partner Matt Caplan is highlighted across press for his recent arrival to the firm's San Francisco office.
July 18, 2025
In the News
David Rosen on FDA's CRL Release – 'It hasn't happened in the past'
Foley & Lardner LLP partner David Rosen commented on the U.S. Food and Drug Administration's decision to publish a package of complete response letters to pharmaceutical companies in the PharmaVoice article, "Why FDA’s CRL release could open the door to lawsuits against pharma."